title: A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
abstract: OBJECTIVE
  This phase II study was designed to determine the overall survival time of adults with supratentorial glioblastoma treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), in combination with and following radiation therapy (RT).
  
  
  METHODS
  This was an open-label, single arm phase II study. Patients were treated with RT in combination with poly-ICLC followed by poly-ICLC as a single agent. Poly-ICLC was initiated 7-28 days after the surgical procedure that established the diagnosis; radiotherapy began within 7 days of the first dose of poly-ICLC and within 35 days of surgical diagnosis. Treatment with poly-ICLC continued following the completion of RT to a maximum of 1 year or until tumor progression.
  
  
  RESULTS
  31 patients were enrolled in this study. One patient did not have a Glioblastoma mutiforme and was deemed ineligible. For the 30 eligible patients, time to progression was known for 27 patients and 3 were censored. The estimated 6-month progression-free survival was 30% and the estimated 1-year progression-free survival was 5%. Median time to progression was as 18 weeks. The 1-year survival was 69% and the median survival was 65 weeks.
  
  
  CONCLUSIONS
  The combined therapy was relatively well-tolerated. This study suggests a survival advantage compared to historical studies using RT without chemotherapy but no survival advantage compared to RT with adjuvant nitrosourea or non-temozolomide chemotherapy. Our results suggest that poly-ICLC has activity against glioblastoma and may be worth further study in combination with agents such as temozolomide.
authors.affiliation: Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143-0350, USA. butowski@neurosurg.ucsf.edu
authors.forename: Nicholas
authors.initials: N
authors.lastname: Butowski
authors.forename: Susan M
authors.initials: SM
authors.lastname: Chang
authors.forename: Larry
authors.initials: L
authors.lastname: Junck
authors.forename: Lisa M
authors.initials: LM
authors.lastname: DeAngelis
authors.forename: Lauren
authors.initials: L
authors.lastname: Abrey
authors.forename: Karen
authors.initials: K
authors.lastname: Fink
authors.forename: Tim
authors.initials: T
authors.lastname: Cloughesy
authors.forename: Kathleen R
authors.initials: KR
authors.lastname: Lamborn
authors.forename: Andres M
authors.initials: AM
authors.lastname: Salazar
authors.forename: Michael D
authors.initials: MD
authors.lastname: Prados
mesh_terms: D000328:Adult; D000368:Aged; D002266:Carboxymethylcellulose Sodium / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011070:Poly I-C / Q000627:therapeutic use*; D011107:Polylysine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods*; D015173:Supratentorial Neoplasms / Q000628:therapy*
chemical_list: D007369:Interferon Inducers; D011107:Polylysine; C019531:poly ICLC; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C
references.citation: J Natl Cancer Inst. 1993 May 5;85(9):704-10
references.pmid: 8478956
references.citation: Tex Rep Biol Med. 1981-1982;41:653-62
references.pmid: 6189230
references.citation: Methods Mol Biol. 2007;383:277-301
references.pmid: 18217692
references.citation: Am J Clin Oncol. 1987 Aug;10(4):281-4
references.pmid: 3039828
references.citation: J Immunol. 1985 Oct;135(4):2483-91
references.pmid: 2411797
references.citation: J Interferon Res. 1991 Aug;11(4):199-205
references.pmid: 1717615
references.citation: Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12
references.pmid: 18262679
references.citation: Endocrinology. 2002 Jun;143(6):2144-54
references.pmid: 12021178
references.citation: Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):351-61
references.pmid: 17681872
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5316-26
references.pmid: 15328167
references.citation: Eur J Cancer. 2007 Jan;43(1):202-9
references.pmid: 17055253
references.citation: J Interferon Res. 1990 Apr;10(2):141-51
references.pmid: 2140395
references.citation: Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10551-5
references.pmid: 7937992
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: J Biol Response Mod. 1985 Oct;4(5):475-80
references.pmid: 2416882
references.citation: Int J Immunopharmacol. 1992 Nov;14(8):1341-53
references.pmid: 1464467
references.citation: J Urol. 1987 Feb;137(2):202-6
references.pmid: 3806804
references.citation: J Biol Chem. 1979 Oct 25;254(20):10180-3
references.pmid: 489592
references.citation: J Neurooncol. 1987;5(4):331-8
references.pmid: 2450181
references.citation: J Transl Med. 2007 Feb 12;5:10
references.pmid: 17295916
references.citation: J Biol Response Mod. 1985 Dec;4(6):656-63
references.pmid: 4087034
references.citation: Gynecol Oncol. 1986 Jul;24(3):359-61
references.pmid: 3721308
references.citation: Cancer. 1993 Apr 15;71(8):2585-97
references.pmid: 8453582
references.citation: Ann N Y Acad Sci. 1980;350:33-41
references.pmid: 6972185
references.citation: Cancer Res. 1985 Mar;45(3):1058-65
references.pmid: 3155990
references.citation: Cancer Res. 1984 Aug;44(8):3252-7
references.pmid: 6204744
references.citation: Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):232-6
references.pmid: 7678339
references.citation: J Neurosurg. 1992 Jul;77(1):120-6
references.pmid: 1318961
references.citation: J Interferon Res. 1982;2(1):1-4
references.pmid: 6180095
references.citation: J Clin Oncol. 1990 Jul;8(7):1277-80
references.pmid: 2358840
references.citation: J Biol Response Mod. 1985 Dec;4(6):640-9
references.pmid: 2418162
references.citation: Cancer Treat Rep. 1986 Nov;70(11):1341-2
references.pmid: 3768878
references.citation: J Biol Response Mod. 1985 Dec;4(6):664-8
references.pmid: 2418164
references.citation: Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4
references.pmid: 8727138
references.citation: Tumour Biol. 1998;19(1):52-9
references.pmid: 9422082
references.citation: Eur J Biochem. 1989 Jan 2;178(3):581-9
references.pmid: 2912723
references.citation: Br J Cancer. 1987 Jul;56(1):89-90
references.pmid: 3620320
references.citation: Immunology. 2008 Aug;124(4):480-8
references.pmid: 18248388
references.citation: Cancer Res. 1992 Jun 1;52(11):3005-10
references.pmid: 1591717
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1375-82
references.pmid: 11870182
references.citation: Expert Opin Pharmacother. 2005 Dec;6(16):2813-20
references.pmid: 16318432
references.citation: Lancet. 2002 Mar 23;359(9311):1011-8
references.pmid: 11937180
references.citation: Cancer Res. 2006 Jan 15;66(2):601-4
references.pmid: 16423984